Streptococcus pneumoniae is a bacterium responsible for pneumonia, meningitis, bloodstream infections, and common childhood ear infections. It ranks among the leading bacterial causes of death in young children worldwide, killing an estimated 179,000 children and adolescents in 2021 alone. Despite its name linking it to pneumonia, this single organism causes a surprisingly wide range of illnesses, from mild sinus infections to life-threatening brain infections.
Basic Biology
Under a microscope, S. pneumoniae cells are lancet-shaped (slightly elongated and pointed) and typically appear in pairs. They stain purple on a Gram stain, classifying them as gram-positive. More than 100 distinct serotypes exist, each defined by the structure of the sugar-based capsule coating the bacterium’s surface. That capsule is far more than a shell. It blocks immune cells from engulfing the bacterium, hides it from the body’s complement system (a set of proteins that tag invaders for destruction), and even helps it slip through the sticky traps that white blood cells deploy.
How It Spreads and Who Carries It
S. pneumoniae travels from person to person through respiratory droplets: coughing, sneezing, or close contact. But most people who pick it up never get sick. The bacterium quietly colonizes the back of the nose and throat, a state called carriage. In a large community study, about 53% of children carried S. pneumoniae at any given time, compared with only about 4% of adults. Carriage rates peak in toddlers aged 2 to 3, where nearly 69% tested positive.
Children are the main reservoir. Household studies consistently show that kids transmit the bacterium to the adults around them, not the other way around. For most carriers, the bacteria eventually clear without causing problems. Disease happens when the organism moves beyond the throat into the lungs, bloodstream, or the membranes surrounding the brain.
How It Overcomes the Immune System
S. pneumoniae is unusually well-equipped to dodge the body’s defenses. Beyond its protective capsule, it produces a toxin called pneumolysin that punches holes in human cells by targeting cholesterol in their membranes. Pneumolysin also reduces the body’s ability to clear mucus, promotes the formation of bacterial communities called biofilms, and interferes with the complement system.
The bacterium’s surface is studded with proteins that each serve a specific evasive function. One blocks complement proteins from tagging it for destruction. Another binds to receptors in the throat to help the bacterium anchor itself during colonization. Yet another hijacks iron-binding proteins in the body, neutralizing a natural antimicrobial defense. Together, these tools make S. pneumoniae remarkably effective at establishing infection in people whose immune systems are weakened, immature, or aging.
Diseases It Causes
Pneumococcal infections fall into two broad categories: mild and invasive.
Mild Infections
Ear infections and sinus infections are the most common illnesses caused by S. pneumoniae, particularly in children. Ear infections cause a red, swollen eardrum along with ear pain, fever, and sleepiness. Sinus infections bring facial pain or pressure, a stuffy or runny nose, post-nasal drip, and sometimes a sore throat or bad breath. These infections are usually treatable and resolve without lasting damage.
Serious Infections
When S. pneumoniae invades normally sterile parts of the body, the consequences are far more dangerous:
- Pneumonia causes chest pain, cough, fever and chills, and difficulty breathing. It is the most recognized pneumococcal disease and can progress rapidly in older adults and people with chronic lung conditions.
- Bacteremia is a bloodstream infection marked by fever, chills, and reduced alertness. It can develop on its own or as a complication of pneumonia.
- Meningitis is an infection of the membranes surrounding the brain and spinal cord. Symptoms include severe headache, stiff neck, fever, confusion, and sensitivity to light. Pneumococcal meningitis is one of the most dangerous forms of bacterial meningitis.
Long-Term Complications
Surviving a serious pneumococcal infection does not always mean a full recovery. Pneumococcal meningitis can leave lasting neurological damage, including hearing loss and cognitive difficulties. Bacteremia is associated with an increased risk of developing new health problems afterward, and severe infections can worsen pre-existing conditions like COPD and heart disease. These long-term consequences are a major reason prevention through vaccination is so heavily emphasized.
Who Is Most at Risk
Age is the strongest risk factor. Children under 5 bear the highest burden: their mortality rate from pneumococcal infections is roughly 24 per 100,000, more than three times the rate across all children and adolescents. Adults over 50 face rising risk as their immune systems gradually weaken.
Beyond age, certain medical conditions significantly raise the odds of severe infection. People with compromised immune systems, those without a functioning spleen, people with cochlear implants, and anyone with a cerebrospinal fluid leak are at particularly high risk. Chronic conditions like COPD, heart disease, and diabetes also increase vulnerability.
Antibiotic Resistance
Treating pneumococcal infections has become more complicated over time. Today, roughly 2 in 5 pneumococcal infections involve bacteria that are resistant to at least one antibiotic. This does not mean the infections are untreatable, but it limits options and can delay effective therapy. Unnecessary antibiotic use is a primary driver of resistance, and inconsistent lab methods for identifying resistant strains make the problem harder to track.
Vaccination
Pneumococcal vaccines are the most effective tool for preventing serious disease. Current recommendations cover two main groups.
For infants and young children, the CDC recommends a four-dose series at 2, 4, 6, and 12 to 15 months of age. Children with certain medical conditions may need additional doses between ages 2 and 18.
For adults 50 and older who have never received a pneumococcal conjugate vaccine, a single dose of one of the newer conjugate vaccines (PCV15, PCV20, or PCV21) is recommended. If PCV20 or PCV21 is used, no additional pneumococcal vaccine is needed. If PCV15 is used, a second vaccine targeting additional serotypes should follow about a year later. Adults younger than 50 with specific risk conditions also qualify for vaccination.
Vaccination has already had a dramatic impact. Global mortality projections suggest that by 2036, the death rate from pneumococcal disease in children and adolescents will drop to roughly 1.6 per 100,000, down from 6.8 per 100,000 in 2021. Wider vaccine coverage, particularly in lower-income countries where the burden remains highest, is key to reaching that goal.